Marvin A Sackner, M.D., Chief Executive Officer and Chairman, Board of
Directors, Non-Invasive Monitoring Systems, Inc. [NIMS]
(OTCBB:NIMU) announced that Professor Masatoshi Fujita and associates,
Shiga University of Medical Sciences, Kyoto University Graduate School
of Medicine, Kitano Hospital, Japan have been awarded a three year
grant-in-aid from April 2008 to March 2011 for a study dealing with NIMS’
flagship product, Exer-Rest®, as a new
treatment for cardiovascular disease. This grant-in-aid was awarded by
the Japanese Ministry of Education, Culture, Sports, Science and
Technology.
Exer-Rest is a Class 2A CE 0120, non-invasive, acceleration platform
which has the configuration of a single or twin bed and is fitted with a
memory foam mattress. Electrical actuation of this device produces whole
body periodic acceleration (WBPA) through repetitive head-foot movement
at about 140 times per minute over a period of 45 minutes. Professor
Fujita’s grant will allow his group to extend
previously published studies in sedentary individuals who showed
improvement of vascular function when treated with WBPA for four weeks.
They pointed out that, “Habitual physical
activity may reduce the risk of cardiovascular disease, but the
prevalence of physical inactivity is increasing.”
They concluded that WBPA “might substitute or
complement active exercise in patients whose medical condition limits
physical activity.”
Dr. Sackner noted that the Japanese government grant to Professor Fujita
is the first to be awarded by a public agency for study of whole body
periodic acceleration in cardiovascular disease. He added that, “NIMS
is pleased to be involved in this study as the supplier of Exer-Rest
medical devices. The Fujita study may demonstrate that whole body
periodic acceleration is a valuable alternative or complementary means
to exercise for the management of cardiovascular diseases.”
A clinical trial is currently underway to support the intended use of
Exer-Rest for temporary relief of musculoskeletal pain associated with
osteoarthritis of the lower extremities (hips and knees) in order to
meet FDA approval for its marketing in the United States.
Further information on the Company can be obtained at www.nims-us.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: The Statements which are not historical facts contained in this
press release are forward-looking statements that involve certain risks
and uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing
requirements, development of new products, government approval
processes, the impact of competitive products or pricing, technological
changes, the effect of economic conditions and other uncertainties
detailed in the Company's filings with the Securities and Exchange
Commission.
|